Gerresheimer achieves all targets in 2014 - Seite 2

especially in the USA and Czech Republic. In fall 2014, Gerresheimer
opened the third development center across the globe in China. A new
plant for the manufacture of injection vials and ampoules currently
under construction in India is scheduled to open in 2015. In the
United States, a large facility will be completely refitted in 2015,
and production technologies are to be further standardized and
improved in numerous other plants around the world.

"Our future success depends on continually improving products,
processes and quality. We are investing worldwide to ensure that we
continue to grow profitably," said Mr. Röhrhoff.

Megatrends are the growth driver in the global healthcare market:
The world's population is increasing, and many people are now living
much longer. Emerging markets are seeing healthcare systems improve,
so more medicines are being sold. Sales of generic drugs are growing
worldwide. Acute and chronic illnesses are on the rise. At the same
time, the standards of quality demanded by patients, pharmaceutical
companies and regulators are becoming more stringent. New medicines
are being developed, requiring new and higher standards of packaging.
Self-medication is also becoming ever more important. As a supplier
of high-quality pharmaceutical packaging and innovative products
enabling safe and easy administration of drugs, Gerresheimer benefits
from all of these megatrends.

Outlook

The Company anticipates organic revenue growth of 1% to 3% for
financial year 2015. This corresponds to a revenue corridor of some
EUR 1,300m to EUR 1,330m at constant exchange rates. Gerresheimer
expects an increase in adjusted EBITDA in a target corridor of EUR
255m to EUR 265m at constant exchange rates. Capital expenditure in
financial year 2015 is forecast to represent around 9% to 10% of
revenues at constant exchange rates.

Gerresheimer is aiming for average annual organic revenue growth
of 4% to 6% for the period from 2016 to 2018. For the adjusted EBITDA
margin, Gerresheimer has defined a target value of 21% for 2018. To
achieve these targets, the Company will continue to require annual
investment of between 9% and 10% of revenues at constant exchange
rates.

Dividend

At the Annual General Meeting on April 30, 2015, the Management
Board and Supervisory Board will be jointly proposing that a dividend
of EUR 0.75 per share be paid out for financial year 2014 (prior
year: EUR 0.70 per share). This represents an increase of 7.1%
against the prior-year dividend. The payout ratio amounts to 26% of
adjusted net income after non-controlling interests.

The Annual Report is available here:
www.gerresheimer.com/en/investor-relations/reports.html

Originaltext: Gerresheimer AG
digital press kits: http://www.presseportal.de/pm/9072
press kits via RSS: http://www.presseportal.de/rss/pm_9072.rss2
ISIN: DE000A0LD6E6

Contact:
Jens Kürten
Group Senior Director Communication & Marketing
Phone [phone]
Telefax [phone]
E-Mail [e-mail]
Website www.gerresheimer.com